Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Rating of “Buy” by Brokerages

by · The Cerbat Gem

Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) has been given a consensus recommendation of “Buy” by the ten analysts that are presently covering the stock, MarketBeat.com reports. Ten equities research analysts have rated the stock with a buy recommendation. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $43.43.

Several equities analysts recently issued reports on SYRE shares. Wedbush began coverage on Spyre Therapeutics in a research report on Wednesday, September 4th. They issued an “outperform” rating and a $45.00 price target on the stock. Evercore ISI began coverage on Spyre Therapeutics in a report on Tuesday, July 16th. They issued an “outperform” rating on the stock.

Check Out Our Latest Analysis on SYRE

Institutional Trading of Spyre Therapeutics

Institutional investors have recently modified their holdings of the business. Amalgamated Bank acquired a new stake in Spyre Therapeutics in the second quarter valued at $28,000. Quest Partners LLC acquired a new stake in shares of Spyre Therapeutics in the second quarter valued at about $36,000. SG Americas Securities LLC purchased a new stake in Spyre Therapeutics during the second quarter worth about $130,000. Carlyle Group Inc. acquired a new position in Spyre Therapeutics during the second quarter worth about $227,000. Finally, Profund Advisors LLC purchased a new position in Spyre Therapeutics in the second quarter valued at about $296,000. 80.39% of the stock is currently owned by hedge funds and other institutional investors.

Spyre Therapeutics Trading Down 1.0 %

SYRE stock opened at $32.43 on Tuesday. The company has a market capitalization of $1.31 billion, a P/E ratio of -0.45 and a beta of 2.92. The business has a 50 day simple moving average of $28.25 and a 200-day simple moving average of $30.47. Spyre Therapeutics has a twelve month low of $8.43 and a twelve month high of $47.97.

Spyre Therapeutics (NASDAQ:SYRE – Get Free Report) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.86) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.90) by $0.04. Research analysts predict that Spyre Therapeutics will post -3.68 EPS for the current fiscal year.

Spyre Therapeutics Company Profile

(Get Free Report

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).

Read More